This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
STERIS (STE) Set to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.
5 Stocks Worth a Buy for Remarkable Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as Hilton Worldwide (HLT), Stride (LRN), Costco Wholesale (COST), Medpace (MEDP) and H&E Equipment Services (HEES) for superb earnings growth.
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth
by Zacks Equity Research
Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.
Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Medpace (MEDP) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 8.82% and 3.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group's (UNH) Arm OptumRx Expands in Arizona
by Zacks Equity Research
UnitedHealth Group (UNH) is set to enhance the offerings of OptumRx with the recent expansion of pharmacy care services in Arizona.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi
by Zacks Equity Research
Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.
Are Medical Stocks Lagging Medpace (MEDP) This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Sinks on Potential Rise in Competition
by Zacks Equity Research
Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.
NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans
by Zacks Equity Research
NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.
DexCom (DXCM) to Launch Latest CGM System G7 in Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Growing Membership, expanding government business, strategic acquisitions, improving operating margin and solid 2024 plans poise UnitedHealth Group (UNH) well for growth.
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
Here's Why Investors Should Retain Humana (HUM) Stock Now
by Zacks Equity Research
Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
by Zacks Equity Research
Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.